Roche secures CE mark for groundbreaking Vaginitis test that promises accurate diagnosis

Roche says its new assay “resolves this challenge by delivering accurate and specific results

Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia

Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval

Indraprastha Medical Corporation posts consolidated Q2 FY26 PAT at Rs. 49.46 Cr

Indraprastha Medical Corporation has reported total income of Rs. 388.40 crore during the period ended September 30, 2025

Amgen’s Phase III data supports FDA label expansion of Repatha

Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention

Lupin acquires VISUfarma to strengthen specialty ophthalmology portfolio

Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr

Shantived Hospital generated revenue of around Rs 50 crore in FY2025

GC Biopharma submits IND to begin Phase 3 clinical trial for Barycela in Thailand

FDA expands Repatha indication to adults at risk of major cardiovascular events from uncontrolled LDL-C

The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia

Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2

The company is addressing these observations comprehensively

Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva